Use access key #2 to skip to page content.
$4.15 0.13 (3.23%)
7/18/2008 4:00 PM

Nektar Therapeutics (NKTR)

CAPS Rating:
**

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating NKTR

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

144 Outperforms
36 Underperforms
 

All-Stars

33 Outperforms
13 Underperforms
 

Wall Street

3 Outperforms
1 Underperforms
 

Players bullish on NKTR are also bullish on:

Players bearish on NKTR are also bearish on:

Ticker Tags

Biotechnology (293), Drug Delivery (22), Small Cap (1922)
Suggest a tag

Nektar Therapeutics At A Glance

Current Price: $4.15
Last Trade Time: 7/18/2008 4:00 PM
Open: $4.01
Previous Close: $4.02
Daily Range: $3.39 - $4.24
52-Week Range: $3.01 - $10.50
Volume: 2,165,397
Market Cap: $371.46M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

NKTR VS S&P 500 (SPY)

NKTR 12 month chart vs. S&P

News & Discussion Boards

Top Bull Pitch

Recs

1

Nektar Therapeutics (NKTR)

Avatar Rugbysdad (74.95) Submitted: 4/09/08 4:38 PM

I closed my under perform (+25%) this morning and opened my out perform (at $5.00) this afternoon.


This stock should really trade back to the $6.50-7.25 range. When Pfizer pulled Exubera, Nektar paid the full price. i believe the stock price prior to this mornings announcement reflected the va...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

Nektar Therapeutics (NKTR)

Avatar honcharella (96.23) Submitted: 3/14/07 7:22 PM

This company just can't make a move upward. One of many with this type of technology and also one of many that just fails to produce results in the form of profits. Maybe one day... Just not today.

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 41 :   1 2 3 4 5 Next »

Recs

0

 (NKTR)

Avatar b3agle (61.27) Submitted: 5/19/08 12:48 PM : Outperform Start Price: $4.58 NKTR Score: 3.02

Turn around already!

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (NKTR)

Avatar Rugbysdad (74.95) Submitted: 4/09/08 4:38 PM : Outperform Start Price: $5.00 NKTR Score: -10.16

I closed my under perform (+25%) this morning and opened my out perform (at $5.00) this afternoon.


This stock should really trade back to the $6.50-7.25 range. When Pfizer pulled Exubera, Nektar paid the full price. i believe the stock price prior to this mornings announcement reflected the value of pipeline products and the net $150 million or so in the bank and discounted Exubera to zero. They do have a pulmonary R&D effort and that will probably get closed down. The net result will be a lower burn rate and better focus on the 2-3 pipeline products in phase II and Phase III. I think it is a buy at this point

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NKTR)

Avatar Aiden1976 (88.84) Submitted: 4/09/08 12:32 PM : Outperform Start Price: $5.06 NKTR Score: -10.99

Because Pfizer want to stop sell the product(inulin inhaler) with NKTR, and the stock got plunge down hard by about 25%. But it will search for another partner to continue sell the product. It might be down for awhile, but I will come back up.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NKTR)

Avatar MattCraig (98.89) Submitted: 4/09/08 9:47 AM : Outperform Start Price: $5.35 NKTR Score: -14.90

did investors really still have exubera in their numbers after pfizer pulled plug last year?

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NKTR)

Avatar gqd911 (< 20) Submitted: 2/19/08 2:21 PM : Outperform Start Price: $6.36 NKTR Score: -28.82

NKTR will outperform their shares in the next two q'S?

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 41 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 4 of 4  

picks per page. CHANGE

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackOppenheimer < 20 03/01/07 03/01/07 Outperform NS $11.86-65.01%-10.56%-54.44
TrackDeutscheSec 89.52 03/01/07 03/01/07 Outperform NS $11.72-64.59%-10.41%-54.18
TrackMJSK < 20 09/28/06 09/28/06 Outperform NS $14.16-70.69%-5.82%-64.87
TrackJimCramer 82.55 08/03/06 08/03/06 Underperform 3W $16.54-74.91%-1.17%+73.74

Results 1 - 4 of 4  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners